JP2007504169A - 修飾されたプロテアーゼインヒビター - Google Patents

修飾されたプロテアーゼインヒビター Download PDF

Info

Publication number
JP2007504169A
JP2007504169A JP2006524951A JP2006524951A JP2007504169A JP 2007504169 A JP2007504169 A JP 2007504169A JP 2006524951 A JP2006524951 A JP 2006524951A JP 2006524951 A JP2006524951 A JP 2006524951A JP 2007504169 A JP2007504169 A JP 2007504169A
Authority
JP
Japan
Prior art keywords
compound
amino acid
peg
conjugate
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006524951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504169A5 (enExample
Inventor
ロバート シー． ラドナー，
アーロン ケー． サトウ，
ミシェル． アマラル，
メアリー ジェイ． ボサード，
マイケル ジェイ． ロバーツ，
ヤン ツァン，
アーサー シー． レイ，
Original Assignee
ダイアックス コーポレーション
ネクター セラピューティックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション, ネクター セラピューティックス filed Critical ダイアックス コーポレーション
Publication of JP2007504169A publication Critical patent/JP2007504169A/ja
Publication of JP2007504169A5 publication Critical patent/JP2007504169A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2006524951A 2003-08-29 2004-08-30 修飾されたプロテアーゼインヒビター Withdrawn JP2007504169A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49884503P 2003-08-29 2003-08-29
PCT/US2004/028256 WO2005021556A2 (en) 2003-08-29 2004-08-30 Modified protease inhibitors

Publications (2)

Publication Number Publication Date
JP2007504169A true JP2007504169A (ja) 2007-03-01
JP2007504169A5 JP2007504169A5 (enExample) 2007-09-13

Family

ID=34272739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524951A Withdrawn JP2007504169A (ja) 2003-08-29 2004-08-30 修飾されたプロテアーゼインヒビター

Country Status (6)

Country Link
US (1) US20070020252A1 (enExample)
EP (1) EP1663279A4 (enExample)
JP (1) JP2007504169A (enExample)
AU (1) AU2004268144A1 (enExample)
CA (1) CA2537113A1 (enExample)
WO (1) WO2005021556A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
JP2012530069A (ja) * 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006070012A1 (en) * 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
PT1981519T (pt) * 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
HUE039108T2 (hu) * 2006-03-16 2018-12-28 Dyax Corp Készítmények és eljárások szembetegségek kezelésére
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20110094080A1 (en) * 2009-10-27 2011-04-28 William Karales Bar soap support mat
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
MX2022008649A (es) 2020-01-13 2022-09-23 Takeda Pharmaceuticals Co Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
PT1489097E (pt) * 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
HU221311B1 (en) * 1994-06-02 2002-09-28 Merrell Pharma Inc Perfluoroalkyl tripeptides inhibitors of elastase, pharmaceutical compositions comprising thereof and their use
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU2346900A (en) * 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
IL149267A0 (en) * 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
US6544760B2 (en) * 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US20020168323A1 (en) * 2001-05-11 2002-11-14 Igor Gonda Optimization of the molecular properties and formulation of proteins delivered by inhalation
HUP0400442A2 (hu) * 2001-05-21 2005-03-29 Nektar Therapeutics Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására
RU2296769C2 (ru) * 2002-07-24 2007-04-10 Ф.Хоффманн-Ля Рош Аг Пэгилированный полипептид т20
WO2004012773A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
JP2012530069A (ja) * 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体

Also Published As

Publication number Publication date
CA2537113A1 (en) 2005-03-10
AU2004268144A1 (en) 2005-03-10
EP1663279A2 (en) 2006-06-07
WO2005021556A3 (en) 2005-12-15
EP1663279A4 (en) 2009-02-18
US20070020252A1 (en) 2007-01-25
WO2005021556A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
JP5396346B2 (ja) ポリペグ化されたプロテアーゼインヒビター
JP2007504170A5 (enExample)
JP2007504169A (ja) 修飾されたプロテアーゼインヒビター
ES2663497T3 (es) Inhibición de proteasas
KR101022577B1 (ko) 항원성이 감소한 중합체 콘쥬게이트, 이의 제조방법 및용도
US20170189544A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
Patil et al. Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation
JP2006512050A (ja) 血清タンパク質結合標的特異的リガンドとその同定方法
EP2850093B1 (en) Therapeutic il-13 polypeptides
US20050164945A1 (en) Endotheliase-1 ligands
HK1092710B (en) Poly-pegylated protease inhibitors
HK1092710A (en) Poly-pegylated protease inhibitors
德榜登 et al. PEG40-F (ab')
HK1083190B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070703

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090323